Applied DNA Sciences (APDN) said Wednesday that its Applied DNA Clinical Labs unit submitted a validation package to the New York State Department of Health for the approval of a test for the detection and subtyping on influenza A (H5) virus.
The influenza A (H5) virus, also known as H5 bird flu, is a highly pathogenic avian influenza, or H5N1, the company said.
The firm said its Linea Avian Influenza H5 Dx assay is a multi-target diagnostic assay capable of detecting and discriminating between pan-influenza A and H5 bird flu.
Price: 2.11, Change: +0.01, Percent Change: +0.48
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.